Rating Change
BMO Capital reiterated its Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on August 19, 2026.
reiterateNASDAQ:ALNY
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals, Inc. (ALNY)
BMO Capital reiterated its Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on August 19, 2026.
At publication ·
What changed
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) · reiterate
- Firm
- BMO Capital
- Rating
- Outperform to Outperform
- Price at event
- $242.61
- Market capitalization
- $44.2B
At a glance
Key takeaways
- BMO Capital reiterated an Outperform rating on Alnylam Pharmaceuticals on August 19, 2026, with the stock trading at $242.61 and a market capitalization of $44.2 billion.
Market Context
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $242.61 with a market capitalization of $44.2B. The stock has declined 46.9% over the past 52 weeks.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alnylam Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Alnylam Pharmaceuticals, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | N/A |
| Aug 14, 2026 | Wells Fargo | Equal-Weight | N/A |
| Aug 04, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 04, 2026 | Truist Securities | Buy | N/A |
| Aug 03, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View ALNY Stock Page
Frequently Asked Questions
What does the Outperform rating mean for ALNY?
A rating of Outperform from BMO Capital reflects the analyst's outlook on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ALNY forecast page.